AstraZeneca (AZN) appears to be stepping back from combination therapy approaches in transthyretin amyloid cardiomyopathy following a significant phase 3 clinical failure. The setback involved Wainua, a drug developed in partnership with
More
Meeting the legal requirements of DSCSA and building genuine operational efficiency are two very different things, according to a senior industry figure. Gregg Gorniak, vice president of manufacturer operations and data services
More
The American Chemical Society (ACS) has announced the winners of its 2026 Green Chemistry Challenge Awards, recognising pioneering work across pharmaceuticals, materials science, agriculture, and semiconductor manufacturing. ACS says the awards “recognize
More
The United States Court of Appeals for the Ninth Circuit has ruled that sports event contracts offered on prediction market exchanges are not “swaps” under the Commodity Exchange Act. The August 28,
More
Major Wall Street banks are pushing large law firms to slash their fees, arguing that artificial intelligence tools can absorb significant portions of traditional legal work. The Financial Times reported that investment
More
At ILTACON 2026 in Nashville, the dominant theme was unmistakable: legal technology vendors are partnering with one another at an unprecedented pace. The conference’s host city made its presence felt immediately, with
More
London stocks retreated on Tuesday following a long weekend, with the FTSE 100 closing down 0.29% as investors confronted a combination of domestic inflation pressures and fresh Middle East tensions. The conflict
More
Equity markets on Wall Street came under pressure as rising oil prices and a broad bond sell-off combined to drag stocks lower across major indices. The dual headwinds rattled investor confidence, with
More
Lost Village, the Lincolnshire-based festival, is being dubbed the “Wilderness of the north” by insiders who know both events well. While Wilderness in the Cotswolds famously offers a nanny service, Lost Village
More
Novartis has announced positive topline results from its Phase 3 REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis. Remibrutinib is a highly selective and potent oral Bruton’s tyrosine kinase inhibitor
More